# A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

> **NCT02497378** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** JNJ-54767414 (Daratumumab)
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02497378
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-10
- **Primary completion:** 2018-03-06
- **Final completion:** 2018-03-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497378, "A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02497378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*